Cyprotex Share Discussion Threads

[buywell2] 04/2/2016 23:27

I made the point that I hoped Cyprotex would make a USA acquisition that enhanced its new BioSciences Division


This is why





''Biotech and pharmaceutical companies pursue targeted and specialized therapies.

Companies have also invested millions in new treatments known as precision or personalized medicine that rely on advances in genomics and big data to target very specific types of cancer or other diseases affecting small groups of patients. For example, a drug called Herceptin, approved in 2006, treats women whose breast cancer has too many copies of a specific gene that manufactures a protein that can stimulate out-of-control cell growth.

PricewaterhouseCoopers notes that 94 percent of companies are invested in research related to personalized medicine, and the Personalized Medicine Coalition says 20 percent of new drug approvals in 2014 went to these treatments. "That's one of the pillars where we believe growth will come from," Reh said. ''

[redprince] 03/2/2016 19:56

Well said on all points Husbod.

[husbod] 02/2/2016 11:54

Buywell - why do they need to raise more cash - they haven't used the previous tranche yet have they? Let's see what we have left when the Results are issued.

I personally don't want any further dilution and neither do I have the spare cash to partake in any further fund raising having subscribed in full to the last one.

Not sure about the States yet either. Let's see what progress they've made in sorting out the problems from the last US acquisition before we think of doing it again. Anyway the existing US business can surely expand organically to further exploit that particular market.

Thought we were going to get near the 120p mark the other day when we were 6p up in the morning and was looking forward to seeing whether there would be a bid - in the context of the removal of the 120p minimum trigger.

[wuzy] 25/1/2016 23:30

Dan. On their website full year results will be around 20th-22nd March as of past years.Cheers

[dan_trader2] 25/1/2016 11:48

When are the full year results due? Thanks

[p1nkfish] 21/1/2016 21:17

probably just a negotiation to get them to drop the performance bonus to keep cash in the business.

don't see it as conspiratorial or negative and bosses well motivated.

[saltaire111] 21/1/2016 19:47

I really do not understand why they're faffing about with this sort of detail over removal of £1.20 minimum level for a takeover. Unless they've already been sounded out by someone at £1.19 a share!!

Salty.

[husbod] 21/1/2016 09:14

Why should they take out the share option's minimum 120p price for the change of ownership?

Surely they wouldn't sell for less than 120 and if not why take the requirement out?

That doesn't send out the right signals.

I also reserve judgement on the waiving of the discretionary performance bonus until we see the actual results for the y/e 31st December 2015. No doubt the directors already have a pretty good indication of what they might be foregoing

[dan_trader2] 19/1/2016 23:11

When's the next full year report due?

[tromso1] 19/1/2016 15:30

Moving up on further decent buying now.

Plenty of upside given the recent sharp drop.

A very good entry opportunity here imo given that the company expects that "full year EBITDA will significantly exceed current market expectations".

[tromso1] 19/1/2016 13:19

Bouncing from the level NT bought them at in December.

"One riskier one to mention! That's Cyprotex (CRX) bought
some for the sipp recently and topped up for the isa today
after a superb trading statement.

CRX expects results to be "significantly" ahead of market expectations -
this nice under the radar company is helping to stop cruel testing on animals and is producing systems to phase out animal testing altogether. Admirable, and potentially profitable too, what you might call a win win.

Risky but a potential doubler."

[rrb] 18/1/2016 19:47

This thing is trading at barely 1.3 x revenues, assuming we get approx £15m for FY16. Most M&A in the life sciences sector is on multiples of 5 x revs. We have a decent 20% sales growth here so current mcap of <£20m is ridiculous! I can only point to the loan notes as the reason why this isn't trading >200p.

[buywell2] 17/1/2016 22:44

Regarding the above


This shows that the area that needs to be improved by the authorities is Pre Clinical trials


The FDA and EMA do not stipulate the use of human living cells from the liver, brain, heart, kidneys and other organs to be used in BOTH in silico AND in vitro Toxicology assays.


It is absolutely disgusting that in 2016 humans become the guinea pigs and as a result die

Politicians need to be held to account










France drug trial: Brain-dead man dies in hospital



A man left brain-dead after an experimental drug trial in France has died, local media report.

He was one of six people being treated in hospital in the city of Rennes.

The hospital said the other five remained in a stable condition - four had "neurological problems" and the fifth had no symptoms.

Reports that the drug was a cannabis-based painkiller have been denied by the French health ministry. The Paris prosecutor has opened an investigation

The trial, which involved taking the drug orally and has now been suspended, was conducted by a private laboratory in Rennes.

Ninety volunteers took the drug, manufactured by the Portuguese company Bial.

Ten of the other 84 have been tested, but did not display any of the "anomalies" of those admitted, the Rennes hospital said in its statement (in French).

On Friday, the chief neuroscientist at the hospital, Gilles Edan, said there was no known antidote to the drug.

Analysis: James Gallagher, health editor, BBC News website

This is the bitter price of the new medicines we take for granted. Testing such experimental drugs, at the cutting edge of science, can never be completely risk-free.

The safety and effectiveness of these drugs are rigorously tested in animals. The risks are low but there must still be a leap of faith when they are tried in people for the first time.

This trial has been taking place since July without such major events being reported. Generally in Phase I trials the dose is increased slowly over time, which could be why the side-effects are appearing now.

The hospitalised men started taking the drug regularly on 7 January and began showing severe side-effects three days later.

It is a high price to pay, but thousands of people do safely take part in similar trials each year.

The trial was conducted by Biotrial, a French-based company with an international reputation which has carried out thousands of trials since it was set up in 1989.

The study was a Phase I clinical trial, in which healthy volunteers take the medication to evaluate the safety of its use, the ministry said.

Before any new medicine can be given to patients, detailed information about how it works and how safe it is must be collected.

Clinical trials are the key to getting that data - and without volunteers to take part in the trials, there would be no new treatments for serious diseases such as cancer, multiple sclerosis and arthritis.

New EU regulations to speed up clinical drug trials and streamline testing procedures across the 28-nation bloc are due to take effect in 2018.
Clinical trials

Trials typically have three phases to assess a new medicine for safety and effectiveness


Phase I tests for safety. A small number of people, sometimes healthy, and sometimes with a medical condition, are given a tiny dose of the drug under careful supervision, not to test if the drug works, but in order to check for any side effects

Phase II sees the drug given to people who have a medical condition to see if it does indeed help them

Phase III trials are only for medicines or devices that have already passed the first two stages, and involve them being compared to existing treatments or a placebo. The trials often last a year or more, involving several thousand patients

[buywell3] 13/1/2016 23:19

I would think any buyer of CRX would think the same

A premium of circa 40% to the share price at the time of any offer seems likely

[curlly] 12/1/2016 12:27

Like wise charliee and I am looking at getting back in if we see 85p

[charlieej] 12/1/2016 12:18

It had a mammoth rise and as such is correcting itself. I sold a decent chunk at 120 personally and am sure there are others taking profits

[mrphil] 12/1/2016 10:33

Ummmm, carried on falling this morning?

[p1nkfish] 11/1/2016 21:15

reckon some stops were taken out as it fell through the psychological £1 barrier.

[mrphil] 11/1/2016 18:03

Bit of an unexpected big fall late on today, anyone know what that's all about?

[buywell3] 10/1/2016 22:48

The chart of Cyprotex has performed well recently

If the recent increase in turnover experienced in the last quarter of 2015 extends through 2016

Then the red resistance line should get taken out , perhaps after the 2015 results are announced with accompanying update/news.

The second red line at 150p could then get challenged if the 2016 interims are better than those of 2015 , eg say 20% better for example.


free stock charts from uk.advfn.com

[buywell3] 05/1/2016 03:15

EPA Releases Screening Data on 1,800 Chemicals, Announces ToxCast Data Challenges

December 23, 2013
by Sustainable Brands



“EPA’s use of cost-effective advanced chemical screening techniques has transformed this country’s knowledge of the safety of almost 2,000 chemicals currently in use,” said Lek Kadeli, acting assistant administrator for EPA’s Office of Research and Development. “[This] release marks an important milestone in communicating and improving our understanding of the impact chemicals have on human health and the environment.

Along with announcing the availability of data on these chemicals of concern, the Environmental Protection Agency has announced the ToxCast Data Challenges, a series of challenges inviting the science and technology community to help provide solutions for how new chemical screening data can be used to predict potential health effects. Challenge winners will receive awards for their innovative research ideas.

The data were gathered through advanced techniques, including robotics and high-throughput screening, as part of an ongoing federal collaboration to improve chemical screening. The collaboration, Toxicity Testing in the 21st Century (Tox21), is comprised of the EPA, the National Institutes of Environmental Health Sciences/National Toxicology Program, National Center for Advancing Translational Sciences and the Food and Drug Administration.

“Making these data publicly available will help researchers across disciplines to better identify hazardous chemicals,” said Raymond Tice, Ph.D., who heads the Biomolecular Screening Branch at the National Institute of Environmental Health Sciences (NIEHS), part of NIH. “We are pleased to be a partner in these collaborative efforts and look forward to further enhancing the amount of Tox21 data available to the public.”

The EPA says only a fraction of chemicals in use in the U.S. have been adequately assessed for potential risk. This information is useful for prioritizing chemicals for potential risk, as well as predicting whether chemical exposures could lead to adverse health effects.

Though California recently adopted groundbreaking regulations promising safer consumer products, in the absence of a stronger federal chemicals policy, a number of consumer products companies have taken it upon themselves to establish guidelines and goals around the phase-out of hazardous chemicals from their supply chains. Seventh Generation requires all ingredients to pass a review of health and environmental safety concerns, conducting independent, third-party laboratories to screen its products annually for chemicals of concern; and Nike, Levi Strauss, H&M and several other members of the Zero Discharge of Hazardous Chemicals Group have committed to publishing a list of chemicals targeted for phase out or research by 2015 as part of a plan to eliminate hazardous chemicals from their supply chains by 2020.

[buywell3] 05/1/2016 03:00

Cyprotex announces the launch of CellCiphr® Premier



20 September 2012 - Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the launch of CellCiphr® Premier, a High Content Screening (HCS) service that combines an extended panel of toxicologically-relevant endpoints with Cyprotex's unique system for classifying cellular responses to drug exposure, to provide one of the most reliable clinical hepatotoxicity predictors available on the market today.



HCS uses fluorescent dyes and fluorescently-labelled antibodies to stain specific regions of the cell which can be used to track processes that may indicate cellular toxicity. Setting up a HCS system is complex and requires a specific skill set, but for those pharmaceutical companies using this technology, it has become part of best practice to pick safer leads (DSEC 2011 Survey).



CellCiphr® Premier offers a panel of toxicologically-relevant endpoints in both replicating and metabolically competent cells which assess compounds at multiple time points to identify early and late stage toxicities. It also incorporates drug plasma concentrations to correct for drug exposure-related effects, which allows for more accurate prediction of potential drug toxicity. CellCiphr® Premier can help assess common toxicity signatures to identify candidates with the lowest potential risk for further drug development.



Commenting on this new offering, Dr. Anthony Baxter, the Chief Executive Officer of Cyprotex, said: "Drug-induced hepatotoxicity is major challenge in the Pharmaceutical Industry. With CellCiphr® Premier we have developed an offering which improves the prediction of hepatotoxicity over existing methods. This new offering complements our comprehensive portfolio of assays developed by Cyprotex to assess potential toxicity issues early in the drug development process, saving pharmaceuticals companies time and money".






ToxCast™ publish CellCiphr® research on the prediction of cellular damage and repair

High Content Screening in HepG2 Cells

Posted 16th December 2015 by Cyprotex

ToxCast™ is a research initiative launched in 2007 by the United States Environmental Protection Agency (US EPA) to screen compounds and gain insight into their toxicological profiles. To date, more than 1800 chemicals have been assessed in high-throughput assays and the data catalogued and released to the public. Cyprotex’s US laboratory in Watertown, MA (previously named Apredica) have contributed to the High Content Imaging (HCI) research for the ToxCastTM project.

The US EPA recently published the results of this study with Apredica, which used Cyprotex’s HCI platform, CellCipr®, to elucidate cell damage caused by chemicals and at which point (either through concentration or exposure time) cells would no longer recover from the damage sustained. The study assessed phenotypic changes of 11 endpoints caused by 967 chemicals at a range of concentrations (up to 200 µM) over a 72 hour exposure period in HepG2 cells. The endpoints included p53, c-Jun, phospho-histone H3, alpha tubulin, mitochondrial membrane potential, mitochondrial mass, cell cycle arrest, nuclear size and cell number. To better understand the toxic properties of these test articles, the rate at which cells reached damage beyond repair, or a “tipping point”, was quantified. Unsurprisingly, compound concentration played a direct role in the speed with which this tipping point was reached. The results broke out quite neatly, with about one-third each showing either irreparable damage, resilience or need for further analysis.

However, there are some notable limitations to this study. First, HepG2 cells are not hepatocytes and as such, behave differently, in part because of their relatively lower metabolic activity. Furthermore, because this study was performed in a 2D monoculture, some of the nuances expressed in a multi cell-type organ may not have been expressed. Additionally, only two time points where examined – 24 and 72-hour. While a little more than one-third of the compounds reached or surpassed the phenotypic tipping point at 72 hours, one-third did not. A subset of the cells that showed recovery capabilities (that is, repairable damage) had not fully recovered by 72 hours. It remains unknown whether recovery would have continued beyond that or maximum, though incomplete, restoration was achieved.

Despite these limitations, the findings demonstrate the utility of High Content Imaging for detection of toxicological response and providing an insight into adaptation and resilience of in vitro cellular systems based on tipping point analysis. It is proposed that this technique has the potential for defining risk-based prioritisation of chemicals.